natgillin/translations-raw huggingface dataset:
Efter gentagen administration med 20 mg esomeprazol én gang dagligt i fem dage mindskes gennemsnitligt peak-syreoutput efter pentagastrinstimulation med 90 % målt 6-7 timer efter dosering på dag fem.
After repeated administration with 20 mg esomeprazole once daily for five days, mean peak acid output after pentagastrin stimulation is decreased 90% when measured 6-7 hours after dosing on day five.
Samtidig administration af 30 mg esomeprazol medførte et fald på 45 % i clearance af CYP2C19-substratet diazepam.
Concomitant administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam.
Kontakt lægen, før du tager Nexium Control, hvis:
Talk to your doctor before taking Nexium Control if:
• Hævede fødder og ankler
• Swelling of the feet and ankles.
A. FREMSTILLERE ANSVARLIGE FOR BATCHFRIGIVELSE
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
Nexium Control må ikke tages som forebyggende lægemiddel over længere tid.
Patients should not take Nexium Control as a long term preventive medicinal product.
Esomeprazol er syrelabil og administreres oralt som entero-overtrukne granulater.
Esomeprazole is acid labile and is administered orally as enteric-coated granules.
Plasmaproteinbindingen af esomeprazol er 97 %.
Esomeprazole is 97% plasma protein bound.
Et klinisk studie viste samtidig administration af 40 mg esomeprazol til patienter i warfarinbehandling, at koagulationstiden lå indenfor det accepterede tidsinterval.
Concomitant administration of 40 mg esomeprazole to warfarin-treated patients in a clinical study showed that coagulation times were within the accepted range.
Andre mulige interaktionsmekanismer er via hæmning af CYP2C19.
Other possible interaction mechanisms are via inhibition of CYP2C19.
Esomeprazol eller dets hovedmetabolitter viser ingen tendens til akkumulation ved dosering én gang dagligt.
Esomeprazole or its major metabolites do not show any tendency to accumulate with once-daily dosing.
I to randomiserede, dobbeltblindede, placebokontrollerede pivotale multicenterforsøg blev 234 forsøgspersoner med nylig forekomst af hyppig halsbrand behandlet med 20 mg esomeprazol i 4 uger.
In two multicentre, randomised, double-blind, placebo-controlled pivotal studies 234 subjects with a recent history of frequent heartburn were treated with 20 mg esomeprazole for 4 weeks.
Hud og subkutane væv dermatitis, pruritus, udslæt, urticaria alopeci, fotosensibilitet erythema multiforme, StevensJohnson syndrom, toksisk epidermal nekrolyse (TEN)
Skin and subcutaneous tissue disorders dermatitis, pruritus, rash urticaria alopecia, photosensitivity erythema multiforme, StevensJohnson syndrome, toxic epidermal necrolysis (TEN)
Nexium Control indeholder det aktive stof esomeprazol.
Nexium Control contains the active substance esomeprazole.
På grund af lignende farmakodynamiske effekter og farmakokinetiske egenskaber for omeprazol og esomeprazol, kan samtidig administration af esomeprazol og atazanavir ikke anbefales, og samtidig administration af esomeprazol og nelfinavir er kontraindiceret (se pkt.
Due to the similar pharmacodynamic effects and pharmacokinetic properties of omeprazole and esomeprazole, concomitant administration with esomeprazole and atazanavir is not recommended and concomitant administration with esomeprazole and nelfinavir is contraindicated (see section 4.3 and 4.4).
• En infektion kaldet ”trøske”, der kan angribe fordøjelseskanalen, og som er forårsaget af svamp
• An infection called “thrush” which can affect the gut and is caused by a fungus.
Kontakt lægen eller apotekspersonalet, hvis:
Talk to your pharmacist or doctor if:
De faste partikler indeholder medicin - de må ikke tygges eller knuses
The solid pieces contain the medicine - do not chew or crush them.
Du må gerne tage dette lægemiddel samtidig med antacida (f.eks. magaldrat, alginsyre, natriumbicarbonat, aluminiumhydroxid, magnesiumcarbonat eller en kombination af disse), hvis du har behov for det.
You may take this medicine with antacids (e.g. magaldrate, alginic acid, sodium bicarbonate, aluminium hydroxide, magnesium carbonate or combinations of these) if needed.
Ca. 78 % af forsøgspersonerne på 20 mg esomeprazol rapporterede første ophør af halsbrand inden for den første behandlingsuge sammenlignet med 52 - 58 % for placebo.
Approximately 78% of the subjects on 20 mg esomeprazole reported first resolution of heartburn within the first week of treatment compared to 52 - 58% for placebo.
Immunsystemet hypersensitivitetsreaktioner, f.eks. feber, angioødem og anafylaktisk reaktion /shock
Immune system disorders hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock
Patienter med tilbagevendende symptomer på fordøjelsesbesvær eller halsbrand, skal gå til lægen regelmæssigt.
Patients with long-term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals.
Esomeprazol er stærkt plasmaproteinbundet, hvilket vanskeliggør dialyse.
Esomeprazole is extensively plasma protein bound and is therefore not readily dialysable.
• Hvis dine reflukssymptomer bliver forværret eller ikke bliver forbedret, efter du har taget dette lægemiddel i 14 dage i træk, skal du kontakte din læge
• If your reflux symptoms get worse or do not improve after taking this medicine for 14 days in a row, you should consult a doctor.
For saquinavir (med samtidig administration af ritonavir) har der været rapporteret om øgede serumværdier (80-100 %) under samtidig behandling med omeprazol (40 mg én gang dagligt).
For saquinavir (with concomitant ritonavir), increased serum levels (80-100%) have been reported during concomitant omeprazole treatment (40 mg once a day).
Hypromellose 2910 (6 mPa·s) Magnesiumstearat
Hypromellose 2910 (6 mPa·s)
• Hvis du får nogen af de symptomer, der er nævnt i punkt 2 i denne indlægsseddel, og hvis det anbefales, at du kontakter lægen eller apotekspersonalet.
• If you experience any of the symptoms detailed in Section 2 of this leaflet and it advises you to talk to your doctor or pharmacist.
Efter gentagen administration af 40 mg esomeprazol var middelarealet under plasmakoncentrationstidskurven ca. 100 % højere i ”poor metabolisers” end i individer med et funktionelt CYP2C19-enzym (”extensive metabolisers”).
After repeated once-daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers).
For atazanavir og nelfinavir har der været rapporteret om nedsatte serumværdier ved samtidig administration med omeprazol, hvorfor samtidig administration ikke kan anbefales.
For atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole and concomitant administration is not recommended.
Tag altid dette lægemiddel nøjagtigt som beskrevet i denne indlægsseddel eller efter de anvisninger, apotekspersonalet har givet dig.
Always take this medicine exactly as described in this leaflet or as your pharmacist has told you.
Lever og galdeveje forhøjede leverenzymer hepatitis med eller uden gulsot leversvigt, hepatisk encephalopati hos patienter med forudeksisterende leversygdom
Hepatobiliary disorders increased liver enzymes hepatitis with or without jaundice hepatic failure, hepatic encephalopathy in patients with pre-existing liver disease
Andelen af patienter, der opretholdt en intergastrisk pH på 4 i mindst 8, 12 eller 16 timer, var for esomeprazol 20 mg 76 %, 54 % henholdsvis 24 %.
The proportion of patients maintaining an intragastric pH above 4 for at least 8, 12 and 16 hours respectively were for esomeprazole 20 mg 76%, 54%, and 24%.
Patienter med svært nedsat leverfunktion bør dog rådgives af en læge, inden de tager Nexium Control (se pkt.
However, patients with severe liver impairment should be advised by a doctor before taking Nexium Control (see sections 4.4 and 5.2).
Nexium Control fås i en pakningsstørrelse med 14 hårde enterokapsler i høj-densitet polyethylen (HDPE) flasker med induktionsforsegling og børnesikker lukning.
Nexium Control is available in a pack size of 14 gastro-resistant hard capsules in high-density polyethylene (HDPE) bottles with an induction seal closure and child resistant closure.
Disse gastriske virkninger hos rotter er resultatet af vedvarende, udtalt hypergastinæmi som følge af nedsat mavesyreproduktion og er observeret efter langvarig behandling af rotter med mavesyresekretionshæmmere.
These gastric effects in the rat are the result of sustained, pronounced hypergastrinaemia secondary to reduced production of gastric acid and are observed after long-term treatment in the rat with inhibitors of gastric acid secretion.
Dette præparat indeholder sukkerkugler (saccharose).
This medicinal product contains sugar spheres (sucrose).
Efter enkeltdosering af 40 mg esomeprazol er middelarealet under plasmakoncentrationstidskurven ca. 30 % højere hos kvinder end hos mænd.
Following a single dose of 40 mg esomeprazole the mean are under the plasma concentration-time curve is approximately 30% higher in females than in males.
Flaske af høj-densitet polyethylen (HDPE) med induktionsforsegling og børnesikker lukning indeholdende 14 enterokapsler.
High-density polyethylene (HDPE) bottle with an induction seal closure and child resistant closure containing 14 gastro-resistant capsules.
Sukkerkugler (saccharose og majsstivelse), Talcum
Sugar spheres (sucrose and maize starch) Talc
Den mavesyrehæmmende virkning fra esomeprazol og andre PPI'er kan muligvis mindske eller øge absorptionen af lægemidler med gastrisk pH-afhængig absorption.
Gastric acid suppression during treatment with esomeprazole and other PPIs might decrease or increase the absorption of medicinal products with a gastric pH dependent absorption.
Samtidig administration af 40 mg esomeprazol medførte en stigning på 13 % i det laveste plasmaniveau af phenytoin hos epilepsipatienter.
Concomitant administration of 40 mg esomeprazole resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients.
Methacrylsyre-ethylacrylat copolymer (1:1) 30 % opløsning Polysorbat 80
Methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30 per cent Polysorbate 80
Der er ingen relevant anvendelse af Nexium Control i den pædiatriske population under 18 år til indikationen ”kortvarig behandling af reflukssymptomer (f.eks. halsbrand og sure opstød)”.
There is no relevant use of Nexium Control in the paediatric population below 18 years of age for the indication of “short-term treatment of reflux symptoms (e.g., heartburn and acid regurgitation)”.
Disse resultater har ingen indvirkning på doseringen af esomeprazol.
These findings have no implications for the posology of esomeprazole.
pantoprazol, lansoprazol, rabeprazol eller omeprazol)
lansoprazole, rabeprazole or omeprazole).
Da esomeprazols metabolitter, men ikke modersubstansen udskilles gennem nyrerne, forventes det ikke, at metaboliseringen forandres hos patienter med nedsat nyrefunktion.
Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be changed in patients with impaired renal function.
Resultater fra studier med raske forsøgspersoner har vist en farmakokinetisk (PK)/farmakodynamisk (PD) interaktion mellem clopidogrel (300 mg loading-dosis/75 mg daglig vedligeholdelsesdosis) og esomeprazol (40 mg oralt dagligt), hvilket resulterede i nedsat eksponering for den aktive metabolit af clopidogrel med et gennemsnit på 40 % og resulterede i mindsket maksimal hæmning af (ADPinduceret) blodpladeaggregering på gennemsnitligt 14 %.
Results from studies in healthy subjects have shown a pharmacokinetic (PK)/pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg orally daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40%, and resulting in decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 14%.
Nexium Control fås i pakningsstørrelser med 7 og 14 enterotabletter i blisterpakninger.
Nexium Control is available in pack sizes of 7 and 14 gastro-resistant tablets in blisters.
Det er påvist, at esomeprazol 20 mg effektivt behandler hyppig halsbrand hos forsøgspersoner, som har fået en dosis daglig i 2 uger.
Esomeprazole 20 mg has been demonstrated to effectively treat frequent heartburn in subjects receiving one dose per 24 hours over 2 weeks.
• Du er over 55 år og har nye eller nyligt forandrede reflukssymptomer.
• You are over 55 and have new or recently changed reflux symptoms.
Esomeprazol må ikke anvendes under amning.
Esomeprazole should not be used during breast-feeding.
Behandling med PPI'er kan derfor forårsage en let forøget risiko for gastrointestinale infektioner såsom Salmonella og Campylobacter og hos indlagte patienter muligvis også Clostridium difficile.
Treatment with PPIs may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile.
• Ophidset sindstilstand, forvirring eller depression
• Feeling agitated, confused or depressed.
Kapslerne må ikke synkes hele.
The capsules should be swallowed whole.
• Læg tabletten i et glas vand uden brus.
• Put the tablet in a glass of still (non-fizzy) water.
Tag altid dette lægemiddel nøjagtigt som beskrevet i denne indlægsseddel eller efter lægens eller apotekspersonalets anvisning.
Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you.
Investigatorernes vurdering af ophør af halsbrand var i overensstemmelse med forsøgspersonernes vurderinger og viste statistisk signifikant forskel mellem esomeprazol (34,7 - 41,8 %) og placebo (8,0 - 11,4 %).
The investigators' assessments of heartburn resolution were consistent with the subjects' assessments, showing statistically significant differences between esomeprazole (34.7% - 41.8%) compared to placebo (8.0% - 11.4%).
Tag ikke Nexium Control
Do not take Nexium Control
En lyserød, aflang, bikonveks, filmovertrukken enterotablet på 14 mm x 7 mm mærket med ”20 mG” på den ene side og ”A/EH” på den anden side.
A light pink, oblong, biconvex, film-coated, gastro-resistant tablet of 14 mm x 7 mm engraved with ‘20 mG' on one side and ‘A/EH' on the other side.
• Alvorlige nyreproblemer
• Severe kidney problems
Ved samtidig administration med PPI'er er det hos nogle patienter rapporteret en stigning i methotrexatniveauerne.
When given together with PPIs, methotrexate levels have been reported to increase in some patients.
En dosis på 20 mg esomeprazol bør ikke overskrides.
Esomeprazole 20 mg should not be exceeded.
Esomeprazols farmakokinetik er undersøgt i doser op til 40 mg to gange dagligt.
The pharmacokinetics of esomeprazole has been studied in doses up to 40 mg b.i.d.
Lægemidler, der vides at inducere CYP2C19 eller CYP3A4 eller begge (såsom rifampicin og perikum (Hypericum perforatum)), kan medføre lavere serumniveauer af esomeprazol ved at øge metaboliseringen af esomeprazol.
Medicinal products known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St. John's wort (Hypericum perforatum)) may lead to decreased esomeprazole serum levels by increasing the esomeprazole metabolism.
Fem dages oral dosering med 20 mg henholdsvis 40 mg esomeprazol opretholdt mavesækkens pH på 4 i en periode på gennemsnitlig 13 henholdsvis 17 timer hos patienter med 24 timers symptomatisk gastroøsofageal reflukssygdom (GERD).
After five days of oral dosing with 20 mg and 40 mg of esomeprazole, intragastric pH above 4 was maintained for a mean time of 13 hours and 17 hours, respectively over 24 hours in symptomatic gastroesophageal reflux disease (GERD) patients.
Lægemidler, der metaboliseres via CYP2C19
Medicinal products metabolised by CYP2C19
Investigatorerne påviste også, at esomeprazol var signifikant mere effektivt end placebo til lindring af sure opstød (58,5 - 63,6 % versus placebo 28,3 - 37,4 %) under evalueringen i uge 2.
The investigators also found esomeprazole to be significantly more effective than placebo in resolving acid regurgitation (58.5% - 63.6% vs placebo 28.3% - 37.4%) during the week 2 evaluation.
Luftveje, thorax og mediastinum bronchospasmer
Respiratory, thoracic and mediastinal disorders bronchospasm
- Øvrige indholdsstoffer: glycerolmonostearat 40-55, hydroxypropylcellulose, hypromellose, magnesiumstearat, methacrylsyre-ethylacrylatcopolymer (1:1) opløsning 30 %, polysorbat 80, sukkerkugler (saccharose og majsstivelse), talcum, triethylcitrat, carmin (E120), indigocarmin (E132), titandioxid (E171), gul jernoxid (E172), erythrosin (E127), allura red AC (E129), povidon K-17, propylenglycol, shellac, natriumhydroxid og gelatine (se afsnit 2, “Nexium Control indeholder saccharose”).
• The other ingredients are: glycerol monostearate 40-55, hydroxypropylcellulose, hypromellose, magnesium stearate, methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30 per cent, polysorbate 80, sugar spheres (sucrose and maize starch), talc, triethyl citrate, carmine (E120), indigo carmine (E132), titanium dioxide (E171), yellow iron oxide (E172), erythrosine (E127), allura red AC (E129), povidone K-17, propylene glycol, shellac, sodium hydroxide, and gelatin (see section 2, “Nexium Control contains sucrose”.)
En anden måde at tage medicinen på
Alternative method of taking this medicine
De typiske symptomer på refluks er en smertefuld fornemmelse i brystet, som stiger op til halsen (halsbrand) og en sur smag i munden (sure opstød).
The normal symptoms of reflux are a painful sensation in the chest rising up to your throat (heartburn) and a sour taste in the mouth (acid regurgitation).
Samtidig administration af esomeprazol og atazanavir kan ikke anbefales (se pkt.
Co-administration of esomeprazole with atazanavir is not recommended (see section 4.5).
Ca. 80 % af nætterne var fri for halsbrand under alle perioder, og 90 % af nætterne var fri for halsbrand i den sidste uge af hvertklinisk studie, sammenlignet med 72,4 - 78,3 % for placebo.
About 80% of nights were heartburn free during all time periods and 90% of nights were heartburn free by week 2 of each clinical study, compared to 72.4 - 78.3% for placebo.
Du må ikke bruge denne medicin under amning.
You should not use this medicine during breast-feeding.
Hvis du har glemt at tage Nexium Control
If you forget to take Nexium Control
Det kan være nødvendigt for din læge at holde øje med dig, når du starter og stopper med at tage Nexium Control.
Your doctor may need to monitor you when you start or stop taking Nexium Control.
Dette lægemiddel anvendes til voksne til kortvarig behandling af reflukssymptomer (f.eks. halsbrand og sure opstød).
This medicine is used in adults for the short-term treatment of reflux symptoms (for example, heartburn and acid regurgitation).
I begge studier var esomeprazol 20 mg betydeligt bedre, sammenlignet med placebo, til opnåelse af det primære mål, fuldstændigt ophør af halsbrand defineret som ingen halsbrand i de seneste 7 dage før det sidste besøg (33,9 - 41,6 % versus placebo 11,9 - 13,7 % (p<0,001).
In both studies esomeprazole 20 mg was significantly better compared to placebo for the primary endpoint, complete resolution of heartburn, defined as no heartburn episodes during the last 7 days prior to the final visit (33.9% - 41.6% vs. placebo 11.9 - 13.7%, (p<0.001).
Hos raske forsøgspersoner medførte samtidig administration af cisaprid og 40 mg esomeprazol en stigning på 32 % i arealet under plasmakoncentrationstidskurven (AUC) og en forlængelse af eliminationshalveringstiden (t½) på 31 %, men der sås ingen signifikant stigning i cisaprids peak-plasmaniveau.
In healthy volunteers, concomitant administration of 40 mg esomeprazole resulted in a 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half-life(t1/2) but no significant increase in peak plasma levels of cisapride.
Hjælpestoffer, som behandleren skal være opmærksom på: Hver hård enterokapsel indeholder 11,5 mg saccharose.
Excipient(s) with known effect Each gastro-resistant hard capsule contains 11.5 mg sucrose.
- Øvrige indholdsstoffer: glycerolmonostearat 40-55, hydroxypropylcellulose, hypromellose, rødbrun jernoxid (E172), gul jernoxid (E172), magnesiumstearat, methacrylsyre-ethylacrylatcopolymer (1:1) opløsning 30 %, mikrokrystallinsk cellulose, syntetisk paraffin, macrogol 6000, polysorbat 80, crospovidon (Type A), natriumstearylfumarat, sukkerkugler (saccharose og majsstivelse), talcum, titandioxid (E171) og triethylcitrat (se punkt 2, ”Nexium Control indeholder saccharose”).
- The other ingredients are glycerol monostearate 40-55, hydroxypropylcellulose, hypromellose, reddish-brown iron oxide (E172), yellow iron oxide (E172), magnesium stearate, methacrylic acid ethylacrylate copolymer (1:1) dispersion 30 per cent, cellulose microcrystalline, synthetic paraffin, macrogol 6000, polysorbate 80, crospovidone (Type A), sodium stearyl fumarate, sugar spheres (sucrose and maize starch), talc, titanium dioxide (E171) and triethyl citrate (see section 2, “Nexium Control contains sucrose”).
Dette skyldes, at kapslen indeholder overtrukne pellets, der sørger for, at medicinen ikke nedbrydes af din mavesyre.
This is because the capsule contains coated pellets, which stop the medicine from being broken down by the acid in your stomach.
I en undersøgelse med raske forsøgspersoner, var der en mindsket eksponering på næsten 40 % af den aktive metabolit af clopidogrel, når der blev givet en fast dosiskombination med esomeprazol 20 mg + acetylsalicylsyre 81 mg samtidigt med clopidogrel, sammenlignet med clopidogrel alene.
In a study in healthy subjects, there was a decreased exposure by almost 40% of the active metabolite of clopidogrel when a fixed dose combination of esomeprazole 20 mg + acetylsalicylic acid 81 mg was given with clopidogrel compared to clopidogrel alone.
Det kan være nødvendigt for din læge at holde øje med dig, når du starter og stopper med at tage Nexium Control
Your doctor may need to monitor you when you start or stop taking Nexium Control
Refluks er tilbageløb af syre fra maven, som stiger op i spiserøret, der kan blive betændt og gøre ondt.
Reflux is the backflow of acid from the stomach into the gullet (“foodpipe”) which may become inflamed and painful.
Brug af anden medicin sammen med Nexium Control
Other medicines and Nexium Control
• Øget svedtendens
• Increased sweating.
• Digoxin (anvendes mod hjerteproblemer)
• Digoxin (used for heart problems)
Behandling med protonpumpehæmmere (PPI) kan forårsage en let forøget risiko for gastrointestinale infektioner såsom Salmonella og Campylobacter, og hos patienter, som er indlagt på hospitalet, muligvis også Clostridium difficile (se pkt.
Treatment with proton pump inhibitors (PPIs) may lead to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile (see section 5.1).
Andre lægemidlers virkninger på esomeprazols farmakokinetik Lægemidler, der hæmmer CYP2C19 og/eller CYP3A4
Effects of other medicinal products on the pharmacokinetics of esomeprazole Medicinal products which inhibit CYP2C19 and/or CYP3A4
• Udvikling af bryster hos mænd
• Enlarged breasts in men
Må ikke anvendes ved allergi over for esomeprazol eller et af de øvrige indholdsstoffer i denne medicin.
Do not use if you are allergic to esomeprazole or any of the other ingredients of this medicine.
• Digoxin (anvendes mod hjerteproblemer).
• Digoxin (used for heart problems).
• Cilostazol (anvendes til behandling af claudicatio intermittens - en tilstand, hvor ringe blodtilførsel til benmuskler forårsager smerter og vanskeligheder med at gå).
• Cilostazol (used to treat intermittent claudication - a condition where poor blood supply to the leg muscles causes pain and difficulty in walking).
Natriumhydroxid Titandioxid (E171)
Sodium hydroxide Titanium dioxide (E171)
• de tidligere har haft mavesår eller har fået foretaget mave-tarm kirurgiske indgreb
• You have had a stomach ulcer or stomach surgery in the past.